NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,475.92 +268.82 (+1.48%) CRUDE OIL
78.30 +0.19 (+0.24%) GOLD FUTURES
2,310.60 +2.00 (+0.09%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
50,813.89 +27.74 (+0.05%)
Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 873.10 |
| Open | 859.80 |
| Bid | 850.60 x 0 |
| Ask | 850.60 x 0 |
| Day's range | 826.70 - 859.80 |
| 52-week range | 504.40 - 932.00 |
| Volume | |
| Avg. volume | 2,678,059 |
| Market cap | 3.795T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 42.74 |
| EPS (TTM) | 19.90 |
| Earnings date | 03 May 2024 |
| Forward dividend & yield | 12.80 (1.50%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 916.72 |
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Insider MonkeyNovo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript May 2, 2024 Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77. NVO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day! And thank […]
Globe NewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the
